Royalty Pharma plc (RPRX)
After hours:
| Previous Close | 27.99 |
| Open | 28.23 |
| Bid | 27.92 x 500 |
| Ask | 27.99 x 400 |
| Day's Range | 27.89 - 28.83 |
| 52 Week Range | 25.92 - 35.09 |
| Volume | |
| Avg. Volume | 2,853,266 |
| Market Cap | 16.71B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 11.06 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.84 (3.00%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | N/A |
- GlobeNewswire
Royalty Pharma Reports First Quarter 2024 Results
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 millionCommitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts. “We con
- GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIR
- GlobeNewswire
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information an
